Energy Foods and Drinks: Global Markets
Report Highlights
The global revenue from energy foods and drinks reached $115.9 billion in 2010 and $123.3 billion in 2011. It is expected to grow to $168.3 billion by 2016, a compound annual growth rate (CAGR) of 6.4%.
Report Scope
Current and projected product forecasts during the forecast period (2011 to 2016) are discussed. New product launches will be discussed. Revenue figures for 2010 are given except where actual results have not been reported, due to the release timing of the report.
The report includes analysis of leading and emerging competitors in the current worldwide energy food and drink market. Profiles of manufacturers of leading products as well as companies with novel products in development are analyzed to define their specific product strategies employed. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current consumer population. Detailed profiles of current market leaders are discussed, as well as companies with innovative products poised to advance within the forecast period.
Products are defined as ready to drink (RTD) products, and other packaging conventions such as powdered sport recovery drinks are explicitly defined in relevant sections of the report.
Within the report, energy drinks as a segment is broken down to include a variety of drink products. Energy drinks are non-alcoholic soft drinks advertised as boosting physical energy, mental alertness and overall well-being. They emphasize energy derived not from the calories they contain, but rather through a choice of caffeine, vitamins and herbal supplements the manufacturer has combined. Energy drinks include products like Red Bull, Monster and RockStar, among others. Sports drinks are non-alcoholic soft drinks containing electrolytes like sodium, potassium and chloride. These drinks are used for rehydration of athletes after strenuous events. Also, they contain a high percentage of sugar, which is intended to restore energy during or after sporting activity or strenuous exercise. Sports drinks include Gatorade G Series and Powerade, among others.
Excluded from the scope of the report are regular sales of coffee and tea, as sold through specialty shops such as Starbucks or Brueggers. In addition, sales of traditional packaged coffee and tea products sold in supermarkets or point of sale at convenience stores are explicitly excluded from the market.
Market figures are based on revenues at the manufacturers’ level and are projected at 2011-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products, and other factors affecting the market
Included in this report are forecasts by product, product category and by company from 2009 through 2016. The study is arranged to offer an overview of the energy drink and energy food market accompanied by product, company, geography, and mechanism of action, with forecasts broken down and covered by geographic region or country. Virtually the entire globe is covered to include prevalence data for each food subsegment.
Health and wellness claims of major products are evaluated with regard to their safety and long-term effects on health. The mechanism of action of major constituents in these products is also reviewed. The status of potential regulation of these food segments by the FDA and regulatory agencies in other countries is reviewed.
Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.
All market share data presented is on a global basis, unless specifically noted.
Analyst Credentials
Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy, where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development. Jackson Highsmith is a pseudonym of the author.